Back to Peptides
Orexin A
Neuroprotective & Cognitive EnhancersOrexin A is a wake-promoting neuropeptide that modulates sleep, alertness, appetite, and cognitive function. It acts on orexin receptors in the brain and is being researched as a treatment for narcolepsy, fatigue, and age-related cognitive decline. Intranasal delivery allows fast CNS uptake for energizing and neurostimulant effects.
Reconstitute
3 mL BAC + 1mg vial
3 mcg/unit
Daily Range
1–5 mg Intranasal
1x daily in the morning or before demanding cognitive activity
Standard Dose
2.5 mg
Cycle
4–8 weeks
then reassess
Orexin Ahypocretinwakefulnesscognitionneuropeptide
Dosing & Reconstitution Guide
In rodent studies, orexin A is typically administered via intracerebroventricular or intranasal routes at 1–5 μg per dose. These are not human-approved uses.
Standard / Gradual Approach
standardPhaseDoseVolume
Week 1100mcg
Week 2150mcg
Week 3200mcg
Week 4250mcg
Protocol Summary
Intranasal: 1x daily in the morning or before demanding cognitive activity · Dose range 1–5 mg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending
Frequency & Cycling
Intranasal
Use 1x daily in the morning or pre-task. Cycle 5 days on, 2 days off if used long-term to prevent desensitization.
🧪 Quick Start
BAC Water
3 mL
Potential Benefits & Use Cases
Orexin A is a research-use-only peptide not approved for clinical applications.
Regulates circadian rhythm and promotes alertness
Studied in narcolepsy and sleep disorder models
Plays a role in reward, motivation, and feeding behavior
Explored in neurodegeneration and mood regulation research
Modulates cholinergic and monoaminergic pathways in the brain
Clinical data Strong preclinical Limited data
Mechanism of Action
→Binds to orexin receptor 1 (OX1R) and orexin receptor 2 (OX2R) in the brain
→Activates neurons in the hypothalamus, brainstem, and cortex
→Promotes sustained wakefulness by modulating dopamine, norepinephrine, histamine, and acetylcholine pathways
→Regulates energy homeostasis, feeding, and reward signaling
Lifestyle & Optimization
timing
Morning or early daytime dosing. Maintain consistent wake time (7–8 AM).
diet
Avoid heavy meals 2–3 hours before bed. Limit caffeine to before 2 PM.
exercise
Physical activity during daylight hours to support circadian rhythm.
sleep
Maintain consistent sleep-wake schedule.
Peptide Research & Preclinical Studies
Evidence-Based Research Findings
Side Effects & Safety
Common Side Effects
• Mild headache
• Nasal dryness
• Increased heart rate
Contraindications & Warnings
• Avoid use in individuals with severe cardiovascular disease or insomnia
• May exacerbate anxiety or restlessness in sensitive users
Long-Term Safety Data
• Limited long-term human data; use cautiously in chronic regimens
🧮 Dose Calculator
Concentration
3.3
mcg/unit
Draw Volume
150
units (1.500 mL)
For a 500 mcg dose, draw 150 units on a U-100 insulin syringe
🧬
Bioavailability & Absorption
SubQ Injection
Rarely used subcutaneously for central nervous effects
Oral Administration
Very low oral bioavailability
Intranasal
High CNS bioavailability via olfactory and trigeminal transport with intranasal delivery
Half-Life
15–30 minutes systemically; CNS effects last longer
Degradation
Metabolized by peptidases in blood and brain
Tissue Specificity
Targets orexin neurons in hypothalamus, cortex, and limbic regions
⚗️
Peptide Details
Molecular Weight
3562.1
Formula
C146H246N44O42S1
Sequence
NH2-CDSPCSVGPGVVGPGVNGVGNGRKSGSKSQTQTQTQTQTQTQTQTQTV-COOH
⚖️
Legal Status & Regulatory
RegionStatus
FDANot Approved
EUNot Approved
AustraliaNot Approved
CanadaNot Approved
Storage Instructions
Lyophilized (Powder)
Store lyophilized powder at 2-8°C
Reconstituted (Mixed)
After reconstitution, maintain at 2-8°C and use within 28-30 days. For intranasal use, transfer to appropriate spray bottle immediately.